Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan

Liver Cancer

Volumn 4, Issue 1, 2015, Pages 39-50

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnosis; Hepatocellular carcinoma; Prognosis; Surveillance screening; Treatment algorithm

Indexed keywords

SORAFENIB;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CHEMOEMBOLIZATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; JAPAN; LIVER ARTERIOGRAPHY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER STRUCTURE; LIVER TRANSPLANTATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

EID: 84945126926     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367727     Document Type: Review

References (59)

1. http://globocan.iarc.fr/Default.aspx
2. Kudo M: Japans successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver Cancer 2012;1:141-143.
3. Mise Y, Sakamoto Y, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, Sugawara Y, Kokudo N: A worldwide survey of the current daily practice in liver surgery. Liver Cancer 2013;2:55-66.
4. Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013;2:73-83.
5. Kudo M: Surveillance, treatment and outcome of HCC in Japan, ILCA Symposium 3 Noevel opportunities for treatment in HCC. ILCA 2014, Kyoto. (http://www.ilca2014.org/programme.aspx).
6. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401.
7. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T: Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011;29:321-325.
8. Kudo M: Alpha-fetoprotein-L3: useful or useless for hepatocellular carcinoma? Liver Cancer 2013;2:151-152.
9. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M, et al: Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-497.
10. Hayashi M, Matsui O, Ueda K, Kawamori Y, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Nonomura A, Nakanuma Y: Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 1999;172:969-976.
11. Kudo M, Tomita S, Tochio H, Mimura J, Okabe Y, Kashida H, Hirasa M, Ibuki Y, Todo A: Small hepatocellular carcinoma: diagnosis with US angiography with intraarterial CO2 microbubbles. Radiology 1992;182:155-160.
12. Ueda K, Matsui O, Kawamori Y, Nakanuma Y, Kadoya M, Yoshikawa J, Gabata T, Nonomura A, Takashima T: Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206:161-166.
13. Kudo M, Hatanaka K, Maekawa K: Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using Sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78(Suppl 1):40-45.
14. Makuuchi M, Hasegawa H, Yamazaki S: Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 1985;161:346-350.
15. Bruix J, Sherman M American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
16. Llovet JM, Ducreux M, et al European Association For The Study Of The Liver European Organisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
17. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
18. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T: Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007;18:365-376.
19. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
20. Bruix J, Llovet JM, Castells A, Monta X, Br C, Ayuso MC, Vilana R, Rods J: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-1583.
21. Llovet JM, Real MI, Montaa X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sol R, Rods J, Bruix J, Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Hussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
23. Kudo M, Matsui O, Izumi N, et al: JSH consensus-based clinical practice guideline for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468.
24. Kim HY, Park JW: Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer 2014;3:9-17.
25. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014;3:119-124.
26. Kudo M: Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer 2013;2:69-72.
27. Liver Cancer Study Group of Japan: General rules for the clinical and pathological study of primary liver cancer. 3rd English edition, Kanehara & Co., Ltd. Tokyo; 2010.
28. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia: Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-664.
29. Theise ND, Park YN, Curado M: P., et al. Hepatocellular carcinoma; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO classification of tumours of the digestive system, ed 4. Lyon, IARC, 2010;205-216.
30. Ichikawa T, Sano K, Morisaka H: Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014;3:97-107.
31. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, Taura K, Yasuchika K, Nitta T, Ikai I, Uemoto S: Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44:793-798.
32. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, Kobayashi S, Gabata T, Zen Y, Yamashita T, Kaneko S, Nakanuma Y: The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056-2066.
33. Matsuda M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, Hiasa Y, Mochizuki T: Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acidenhanced hepatobiliary phase in patients with chronic liver diseases. Jpn J Radiol 2014;32:405-413.
34. Jang KM, Kim SH, Kim YK, Choi D: Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiol 2014 (Epub ahead of print).
35. Komatsu N, Motosugi U, Maekawa S, Shindo K, Sakamoto M, Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, Araki T, Enomoto N: Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. Hepatol Res 2014:44:1339-1346.
36. Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, Delle Fave G, David V: Gadoxetic acidenhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med (Torino) 2014;119:367-376.
37. Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, Kudo M: Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOBDTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors. Dig Dis 2013;31:472-479.
38. Ichikawa S, Ichikawa T, Motosugi U, Sano K, Morisaka H, Enomoto N, Matsuda M, Fujii H, Araki T: Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma. J Magn Reson Imaging 2014;39:293-297.
39. Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, Kaneoka Y, Maeda A: Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol 2013;58:1174-1180.
40. Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T: Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013;266:480-490.
41. Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D: Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 2012;265:104-114.
42. Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A: Intranodular signal intensity analysis of hypovascular high-risk borderline lesions of HCC that illustrate multi-step hepatocarcinogenesis within the nodule on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 2012;81:3839-3845.
43. Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A: Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 2012;81:3002-3009.
44. Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kawai K, Kozaka K: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 2011;35:181-186.
45. Joishi D, Ueno A, Tanimoto A, Okuda S, Masugi Y, Emoto K, Okuma K, Sakamoto M, Imai Y, Kuribayashi S: Natural course of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging: presence of fat is a risk factor for hypervascularization. Magn Reson Med Sci 2013;12:281-287.
46. Motosugi U: Hypovascular hypointense nodules on hepatocyte phase gadoxetic acid-enhanced MR images: too early or too progressed to determine hypervascularity. Radiology 2013;267:317-318.
47. Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, Mochizuki T: Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acidenhanced MRI in patients with chronic liver disease. Jpn J Radiol 2012;30:743-751.
48. Takayama Y, Nishie A, Nakayama T, Asayama Y, Ishigami K, Kakihara D, Ushijima Y, Fujita N, Hirakawa M, Honda H: Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. Eur J Radiol 2012;81:3072-3078.
49. Akai H, Matsuda I, Kiryu S, Tajima T, Takao H, Watanabe Y, Imamura H, Kokudo N, Akahane M, Ohtomo K: Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 2012;81:2973-2977.
50. Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, Amemiya F, Enomoto N, Matsuda M, Fujii H, Araki T: Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34:88-94.
51. Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, Ishikawa T: Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011;197:58-63.
52. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
53. Kudo M, Lencioni R, Ye SL, et al: ILCA 2013, Washington D.C. http://webcasts.nextmeeting.eu/event/ilca2013/presentation/130.
54. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
55. Kudo M: Recent advances in bioinformatics reveal the molecular heterogeneity of hepatocellular carcinoma. Liver Cancer 2014;3:68-70.
56. Yoneda N, Matsui O, Kitao A, Kozaka K, Gabata T, Sasaki M, Nakanuma Y, Murata K, Tani T: Beta-cateninactivated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 2012;30:777-782.
57. Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang X, Kaneko S: Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014;60:1674-1685.
58. Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, Gabata T, Yamashita T, Kaneko S, Nakanuma Y, Kita R, Arii S: Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 2012;265:780-789.
59. Yoneda N, Matsui O, Kitao A, Kita R, Kozaka K, Koda W, Kobayashi S, Gabata T, Ikeda H, Nakanuma Y: Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature. Jpn J Radiol 2013;31:480-490.